Skip to main
  1. Stocks
  2. McKesson
  3. Forecast
MCK

McKesson (MCK) Stock Forecast & Price Target

McKesson (MCK) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 36%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

McKesson is benefiting from a broad-based beat-and-raise, with specialty prescription volume growth, including GLP-1s, driving stronger-than-expected performance across core North American Pharma and O&M, while O&M operating income rose 23% on an adjusted basis. Its earnings power is being reinforced by operating leverage, stable end markets, and strategic acquisitions such as Precision Medicine Group, Spectrum Vision, and Option Care Health, which expand oncology, clinical research, and wraparound specialty services; management also raised adjusted EPS guidance by $1.40. With earnings growth now expected at 17-19% versus 13-16% under its long-range plan, plus >99% order accuracy and a high-growth specialty drug mix, the company appears well positioned to sustain above-peer fundamentals and long-term valuation upside.

Bears say

McKesson is facing a deteriorating risk-reward profile because its growth increasingly depends on RxTS and BioPharma Solutions just as GLP-1 prior authorizations are leveling off and employer coverage is eroding, putting roughly 9.5%-11.5% of RxTS revenue, or about $560-$660 million, at risk. Regulatory overhang is another major drag, since 2028 Part B Maximum Fair Price negotiations could cut prices by 40%-60% on about $28 billion of Medicare drug spend, threatening the specialty mix that supports differentiated returns. With core distribution margins already razor thin and competition, biosimilar steerage, and slower automation gains all pressuring margins, the company may struggle to sustain the 11-15% operating income growth target.

McKesson (MCK) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 36% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of McKesson and is not a guaranteed prediction by Public.com or investment advice.

McKesson (MCK) Analyst Forecast & Price Prediction

Get the latest McKesson (MCK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in McKesson (MCK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About McKesson (MCK) Forecast

Analysts have given McKesson (MCK) a Buy based on their latest research and market trends.

According to 11 analysts, McKesson (MCK) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,114.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,114.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

McKesson (MCK)


McKesson (MCK) Analyst Forecast & Price Prediction

Get the latest McKesson (MCK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in McKesson (MCK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MCK stock data and trends